Mitral Regurgitation - Valvular Heart Disease Guidelines

Valvular Heart Disease

ACC/AHA Valvular Heart Disease - Mitral Regurgitation GUIDELINES Apps brought to you charge courtesy of Guideline Central and Abbott Vascular.

Issue link: https://eguideline.guidelinecentral.com/i/362036

Contents of this Issue

Navigation

Page 20 of 59

Valve Hemodynamics a Hemodynamic Consequences Symptoms Normal transmitral flow velocity None None • Increased transmitral flow velocities • MVA >1.5 cm 2 • Diastolic pressure half-time <150 ms • Mild-to-moderate LA enlargement • Normal pulmonary pressure at rest None • MVA ≤1.5 cm 2 (MVA ≤1.0 cm 2 with severe MS) • Diastolic pressure half-time ≥150 ms (Diastolic pressure half-time ≥220 ms with severe MS) • Severe LA enlargement • Elevated PASP >30 mm Hg None • MVA ≤1.5 cm 2 (MVA ≤1.0 cm 2 with very severe MS) • Diastolic pressure half-time ≥150 ms (Diastolic pressure half-time ≥220 ms with very severe MS) • Severe LA enlargement • Elevated PASP >30 mm Hg • Decreased exercise tolerance • Exertional dyspnea a e transmitral ΔPmean should be obtained to further determine the hemodynamic effect of the MS and is usually >5-10 mm Hg in severe MS. However, due to the variability of the ΔPmean with heart rate and forward flow, it has not been included in the criteria for severity. 19

Articles in this issue

view archives of Mitral Regurgitation - Valvular Heart Disease Guidelines - Valvular Heart Disease